Trial Profile
Efficacy of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma: A phase II study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2017
Price :
$35
*
At a glance
- Drugs Veliparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 19 Dec 2017 New trial record
- 07 Dec 2017 Results published in the European Journal of Cancer